Sanofi sees major China boost from heart, diabetes drugs, exec says

[Grayman]

-China sales of Sanofi's ($SNY) heart and diabetes drugs contributed heavily to sales growth in the country last year, with the market witnessing twice the growth of the rest of the world combined.

The France-based company said it measured China sales growth of 8.8%, compared with 4.9% in the rest of the world.

The senior vice president of the company's Sanofi Asia and Sanofi China offices said at a news briefing the firm expects vaccines and diabetes drugs to drive sales growth in the coming year.